Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)
February 20 2019 - 9:41AM
Edgar (US Regulatory)
Filed by Bristol-Myers Squibb Company
Pursuant to Rule 425 of the Securities Act of 1933
and deemed filed pursuant to Rule 14a-12
of the Securities Exchange Act of 1934
Form S-4 File No.: 333-229464
Subject Company: Celgene Corporation
SEC File No.: 001-34912
Explanatory Note: The following slides were used by Bristol-Myers Squibb Company at an investor presentation on February 20, 2019.
Celgene (NASDAQ:CELG)
Historical Stock Chart
From Jul 2024 to Jul 2024
Celgene (NASDAQ:CELG)
Historical Stock Chart
From Jul 2023 to Jul 2024